CD36 and prostate carcinoma: In vivo, ablation of SR-B2/CD36 in the prostate tissue of Pten-deficient mice reduced fatty acid uptake by ~ 55%, while treating mice harboring PDXs of localized high-risk prostate cancer with a SR-B2/CD36 mAb reduced fatty acid uptake by 22% [52].